Dublin, Jan. 25, 2021 (GLOBE NEWSWIRE) -- The "Whole Genome And Exome Sequencing Markets - By Research, Clinical, Direct to Consumer, AgriBio & Tumor with Executive and Consultant Guides 2020 to 2024" report has been added to ResearchAndMarkets.com's offering.
Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?
A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well-funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.
Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
The research makes you the expert in your organization.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.
Key Topics Covered:
1. Introduction and Market Definition
1.1 Whole Genome Sequencing Definition In This Report
1.1.1 Whole and Exome Sequencing
1.1.2 Research and Clinical
1.1.3 Direct to Consumer
1.1.5 Tumor Cells
1.2 The Genomics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for laboratory testing
1.5 Sizing the Genome - Not What You Think
1.5.1 Cost, Price and Genome Size, Pricing Practice
2. Market Overview
2.1 Market Participants Play Different Roles
2.1.1 Instrument Manufacturer
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 DTC Lab
2.1.9 Sequencing Labs
2.1.10 Audit body
2.2 Whole Genome Sequencing -Markets, Examples and Discussion
2.2.1 Direct to Consumer - Two Approaches
220.127.116.11 The New Age of Medical Information
18.104.22.168 Dangers in DTC-WGS - Health Costs and Regulation
22.214.171.124 Newborn and Prenatal - A Brave New World
126.96.36.199 DTC - How Many Segments?
2.2.2 Research Markets
188.8.131.52 Research Funding and Capital Expense
184.108.40.206 WGS Datasets Preferred
220.127.116.11 Existing research repurposed
18.104.22.168 Organism Wide Market
22.214.171.124 Service Suppliers Respond
2.2.3 Clinical - Understanding Germline and Somatic
126.96.36.199 Somatic - Chasing Mutations and Pharmacogenomics
2.2.4 Pathogen Testing
188.8.131.52 The Hepatitis C Story
184.108.40.206 Will the Microbiology Department Disappear?
2.2.5 AgriBio - Big Business
220.127.116.11 GMO is Here to Stay
18.104.22.168 WGS Benefits and Risks
22.214.171.124 The New Agriculture
2.3 Industry Structure
2.3.1 Hospital's Testing Share
2.3.2 Economies of Scale
2.3.3 Instrument Manufacturer Role
2.3.4 Healthcare Industry Impacts - Still Struggling
126.96.36.199 Can the Healthcare Industry Adapt?
188.8.131.52 Genetic Counselling as an Industry
184.108.40.206 WGES Adoption and Cannibalization
220.127.116.11 The Meaning of Grail
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Diagnostic Factors
3.1.2 Interpreting the Code Otherwise
3.1.3 Changes in Agriculture.
3.1.4 Fertility Technology Comes of Age
3.1.5 Pathogen Challenges
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs
3.2.3 Healthcare Cost Concerns Curtail Growth
3.2.4 Wellness has a downside
3.2.5 GMO Opposition Movement.
3.3 Sequencing Instrumentation
3.3.1 Instrumentation Tenacity.
3.3.2 Declining Cost of Instruments Changes Industry Structure.
3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.
3.3.4 Oxford Nanopore
18.104.22.168 What is Oxford Nanopore Sequencing?
22.214.171.124 What can Oxford Nanopore Sequencingt be used for?
126.96.36.199 Oxford Nanopore Products
3.3.5 Long Reads - Further Segmentation
3.3.6 Linked Reads
3.3.7 Targeted Sequencing Adopts CRISPR
3.3.8 New Sequencing Technologies
4. WGES Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
UK Whole-Genome Sequencing Project Obtains 200M
WGS may help with disease outbreaks
Veritas Cuts WGS Price by 40%
Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
Machine-learning system used to diagnose genetic diseases
Whole Genome Sequencing for healthy creates controversy
100,000 whole genomes sequenced in the NHS
Nebula Genomics Offers FREE Whole Genome Sequencing
Veritas Genetics has time limited WGS offer for $199
Veritas Genetics Launches Two New Whole Genome Sequencing Products
BGI unveils a powerful new sequencer
State of California Funds $2M Whole-Genome Sequencing Pilot
Rapid genome sequencing could revolutionize health care
Human Longevity Launches Whole Genome Product, MassMutual Partnerships
$1500 to sequence newborns in China
Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
PerkinElmer Launches Clinical Whole Genome Sequencing Services
Nine Centres use Oxford Nanopore MinION to Sequence Human Genome
Esperite and BGI Genomics sign a strategic agreement to offer Whole Genome
Sequencing on a large scale
Easily Affordable Whole-genome Sequencing is Goal of Mayo Collaboration with Veritas
Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK
MedGenome Expands Its NGS Capabilities and Forays Into Single-Cell Sequencing
Genomics England Adopts Edico's Dragen For NGS Analysis
BGI Says It Will Slash Cost of Gene Testing to $300
Position Statement Spells Out Fetal Diagnostic Sequencing Recommendations
Dante Labs Announces 10,000 European Genome Project
5. Profiles of Key Companies
10x Genomics, Inc
Admera Health, LLC
Agena Bioscience, Inc
Baylor Miraca Genetics Laboratories
Beckman Coulter, Inc
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bio-Rad Laboratories, Inc.
Caris Molecular Diagnostics
Complete Genomics, Inc. - A BGI Company
Datar Cancer Genetics Limited
FUJIFILM Wako Diagnostics
GE Global Research
GE Healthcare Life Sciences
Gene by Gene, Ltd
Genetron Health (Beijing) Co., Ltd.
Genomics Personalized Health (GPH)
HTG Molecular Diagnostics
Human Longevity, Inc
MDNA Life SCIENCES, Inc
Novogene Bioinformatics Technology Co., Ltd
Oxford Nanopore Technologies
Personal Genome Diagnostics
Roche Molecular Diagnostics
Singlera Genomics Inc
Sure Genomics, Inc
Tempus Labs, Inc
Thermo Fisher Scientific Inc
6. Global Market Size
6.1 Global Market by Country
6.2 Global Market by Application
7. Market Sizes by Application
7.1 Research Market
7.2 Clinical Market
7.3 Tumor Market
7.4 DTC WEGS Market
7.5 Agribio & Other Market
8. Market Sizes by Coverage
8.1 Genome Market
8.2 Exome Market
8.3 Other Coverage Market
9. Vision of the Future of Whole Genome Sequencing
For more information about this report visit https://www.researchandmarkets.com/r/j73khq
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900